Effects of Mesenchymal Stem Cell Treatment on the Expression of Matrix Metalloproteinases and Angiogenesis during Ischemic Stroke Recovery by 沅뚯씪 et al.
RESEARCH ARTICLE
Effects of Mesenchymal Stem Cell Treatment
on the Expression of Matrix
Metalloproteinases and Angiogenesis during
Ischemic Stroke Recovery
Hyo Suk Nam1,2, Il Kwon1,2, Bo Hyung Lee1,2, Haejin Kim1,2, Jayoung Kim1,2, Sunho An1,2,
Ok-Hee Lee1,2, Phil Hyu Lee1, Hyun Ok Kim3, Hyun Namgoong4, Young Dae Kim1,2, Ji
Hoe Heo1,2*
1 Department of Neurology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea,
2 Severance Integrative Research Institute for Cerebral & Cardiovascular Disease, Yonsei University Health
System, Seoul, Korea, 3 Department of Laboratory Medicine, Severance Hospital, Yonsei Cell Therapy
Center, Yonsei University College of Medicine, Seoul, Korea, 4 Microbiology, Immunology and Molecular
Genetics, University of California Los Angeles, Los Angeles, California, United States of America
* jhheo@yuhs.ac
Abstract
Background
The efficacy of mesenchymal stem cell (MSC) transplantation in ischemic stroke might
depend on the timing of administration. We investigated the optimal time point of MSC
transplantation. After MSC treatment, we also investigated the expression of matrix metallo-
proteinases (MMPs), which play a role in vascular and tissue remodeling.
Methods
Human bone marrow-derived MSCs (2 × 106, passage 5) were administrated intravenously
after permanent middle cerebral artery occlusion (MCAO) was induced in male Sprague-
Dawley rats. First, we determined the time point of MSC transplantation that led to maximal
neurological recovery at 1 h, 1 day, and 3 days after MCAO. Next, we measured activity of
MMP-2 and MMP-9, neurological recovery, infarction volume, and vascular density after
transplanting MSCs at the time that led to maximal neurological recovery.
Results
Among the MSC-transplanted rats, those of the MSC 1-hour group showed maximal recov-
ery in the rotarod test (P = 0.023) and the Longa score (P = 0.018). MMP-2 activity at 1 day
after MCAO in the MSC 1-hour group was significantly higher than that in the control group
(P = 0.002), but MMP-9 activity was not distinct. The MSC 1-hour group also showed
smaller infarction volume and higher vascular density than did the control group.
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Conclusions
In a permanent model of rodent MCAO, very early transplantation of human MSCs (1 h after
MCAO) produced greater neurological recovery and decreased infraction volume. The ele-
vation of MMP-2 activity and the increase in vascular density after MSC treatment suggest
that MSCs might help promote angiogenesis and lead to neurological improvement during
the recovery phase after ischemic stroke.
Introduction
Mesenchymal stem cell (MSC) therapy might improve the functional outcome in stroke, and
the efficacy of MSC therapy might differ depending on the timing of administration [1, 2].
Cell therapy is likely to be ineffective if it is administrated after an optimal time point. The
Stem Cell Therapy as an Emerging Paradigm for Stroke guidelines encourage using a well-
defined therapeutic window in stem cell research [3]. Although early rather than late MSC
treatment might produce a greater effect on stroke recovery, only a few studies have investi-
gated MSC transplantation during the hyperacute period [4–6]. A study conducted to com-
pare effectiveness of intravenous (IV) MSCs treatment at the wide range of time windows
from 3h to 72 h. The earliest transplantation showed smallest lesion volume [7]. Whereas,
intra-arterial (IA) administration of a low dose of MSCs at 1 h after transient MCAO for 90
min did not reduce neurological deficits and infarction [8]. Therefore, optimal timing of
MSCs is uncertain.
The mechanism by which MSC therapy benefits stroke recovery remains unclear. MSC ther-
apy might promote stroke recovery through multiple mechanisms, including induction of
angiogenesis and neurogenesis, prevention of apoptosis, and immunomodulation [9]. MSCs
can stimulate angiogenesis and increase the total surface area of vessels in the ischemic bound-
ary zone [10, 11]. MSCs secrete several cytokines and growth factors, including the pro-angio-
genic molecules vascular endothelial growth factor (VEGF)/VEGF receptor 2 and
angiopoietin/Tie2, directly or through endogenously induced mechanisms [11]. MSCs also
secrete several matrix metalloproteinases (MMPs) [12, 13].
MMPs are a family of proteinases that degrade the extracellular matrix (ECM) [14, 15].
MMPs function as key enzymes under physiologic and pathologic conditions that require
the degradation of ECM molecules, such as during cell differentiation, cell migration, and
tissue injury and remodeling. MMPs have been suggested to play a dual role in stroke [16,
17]. Aberrantly secreted or activated MMPs exert harmful effects in ischemic injury by
destroying the blood-brain barrier and compromising the integrity of the neurovascular unit
[18, 19]. Conversely, MMPs might play beneficial roles during the recovery phase after cere-
bral ischemia by digesting degraded debris and mediating plasticity and remodeling [20].
MMP-2 is associated with angiogenesis, which might contribute to recovery after stroke
[21]. Given the role played by MMPs in modulating the ECM and angiogenesis, the pro-
angiogenic effect of MSC therapy could be mediated by MMPs.
In this context, we explored the optimal time point of MSC administration in cerebral ische-
mia and investigated the change in MMP activity after MSC treatment that can contribute to
angiogenesis and recovery from ischemic stroke.
MSC Therapy and MMP Changes in Ischemic Stroke
PLOS ONE | DOI:10.1371/journal.pone.0144218 December 4, 2015 2 / 16
Research Program through the National Research
Foundation of Korea (NRF) funded by the Ministry of
Science, ICT & Future Planning (NRF-
2014R1A1A1005913) (IK). The funders had no role in
study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
Methods
Ethics statement
This study was approved by the Severance Hospital Institutional Review Board (4-2008-0643)
and written informed consents were obtained from all volunteers who agreed to the use of their
cells for research purposes. Care and use of animals in our experiments were based on the
institutionally approved protocol, in accordance with the Guide for the Care and Use of Labo-
ratory Animals of the National Institutes of Health. The protocol for all animal experiments
was approved by the Institutional Animal Care and Use Committee of Yonsei University Col-
lege of Medicine (08–224). All surgeries and injections were performed under isoflurane inha-
lation anesthesia, and all efforts were made to minimize suffering. Animals were weighted daily
and cirteria of humane endpoints were loss of their body weight more than 20%, any moribund
or comatose animals with labored respiration, and end of experiments. Animals with a humane
endpoint were sacrificed with intraperitoneal injection of overdose of Zoletil 50 (10 mg/kg,
Vibac Laboratories, Carros, France).
Induction of the middle cerebral artery occlusion
Male Sprague-Dawley rats weighing 270–400 g (minimum 276 g, maximum 364g) with the
mean age of 9 to 11 weeks (mean 10 weeks) were subjected to permanent MCAO, as described
previously [22]. Briefly, rats were anesthetized through inhalation of 1.5%–2% isoflurane
mixed with 70% N2O and 30% O2. The body temperature was monitored using a thermometer
and was maintained at 37 ± 0.5°C by using a homeothermic blanket (Harvard Apparatus Ltd.,
Watford, UK) during the surgery. Physiologic parameters such as pH, PaCO2, PaO2, and
hemoglobin were assessed 10 min before and after MCAO. The left carotid artery of the rats
was exposed through midline incision of the neck. After ligating the common carotid, the
external carotid, and the pterygopalatine arteries, a 4–0 monofilament nylon suture (Ethicon,
Edinburg, UK), which was rounded using a flame and treated with poly-L-lysine, was inserted
into the internal carotid artery through a stump in the occluded external carotid artery. The
middle cerebral artery was occluded permanently by advancing the nylon suture further up to
17.5 mm from the common carotid bifurcation. All animals were continuously monitored
from surgery to recovery. After awakening from inhalation anesthesia, we observed for 1 hour.
Daily observation and weight measurement were done during experiment.
Neurologic assessment
Neurologic deficits were assessed using the rotarod test, the Longa score, and the modified
Neurologic Severity Score (NSS) test before and after MCAO.
Rotarod test. The rats were placed on the rotarod cylinder, and the time for which the ani-
mals remained atop the rotarod was measured. The rotarod speed was slowly increased from 4
to 40 rpm over 5 min. A trial ended if the animal fell off the rungs or if it gripped the device
and spun around for 2 consecutive revolutions without attempting to walk on the rungs. The
animals were trained daily for 3 days before MCAO. The mean duration (in seconds) for which
the animals remained on the rotarod cylinder was recorded based on the measurements of 3
trials one day before the surgery [23]. Follow-up tests`were performed at 1, 4, and 7 days
(model 47700, Ugo Basile, Italy for Experiment 1) and 1, 4, 7, 10, and 14 days (Letica LE8500,
Bioseb, France for Experiment 2) after MCAO.
Longa score. Rats were graded on a 5-point scale, which was modified from the Longa
score [24]. Four items were evaluated and 1 point was assigned to each item when an animal
(1) failed to grasp the edge of a table when it was hung by its tail; (2) failed to extend the right
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forepaw fully; (3) exhibited a circling motion toward the paretic side when attempting to walk;
and (4) fell to the lateral side when pushed gently. The 4 items were summed to obtain a total
score. Thus, an animal without any neurologic deficit received a score of 0, whereas an animal
that exhibited maximal deficits received 4 points [24, 25].
Modified Neurologic Severity Score. The modified NSS test was performed before
MCAO and 1, 4, 7, 10, and 14 days after MCAO. A modified NSS test is used to assess motor
(6 points), sensory (2 points), balance (6 points), and reflex (4 points) functions. A rat without
neurologic deficits receives a score of 0, whereas a rat that exhibits the most severe neurologic
deficits receives 18 points [26].
Study design
Experiment 1: We first determined the optimal time point of MSC administration after
MCAO in rats. The optimal time point was defined as the time point of MSC injection that
led to maximal neurologic recovery. In this experiment, MSCs were injected intravenously at
1 h (MSC 1-hour group, n = 7), 1 day (MSC 1-day group, n = 7), or 3 days (MSC 3-day
group, n = 7) after MCAO. The control group received normal saline after MCAO (n = 8).
Neurologic deficits were assessed using the rotarod test and the Longa score before MCAO
and at 1, 4, and 7 days after MCAO. The MMP activity was measured after sacrificing the
animals at 7 days after MCAO (Fig 1A).
Experiment 2: The results of Experiment 1 showed that maximal neurologic recovery
occurred in the group that received MSC transplantation at 1 h after MCAO. Therefore, in
Experiment 2, MSCs were administered at 1 h after MCAO. The rats were divided into a
group that received an MSC injection at 1 h after MCAO (n = 34) and a control group that
received an injection of normal saline (n = 34). We compared the neurologic deficits of the
MSC-treated group and the control group after MCAO based on the results of the rotarod
test and the modified NSS, infarction size, MMP-2 and MMP-9 activities, and vascular den-
sity (Fig 1B).
Isolation and maintenance of human MSCs
Bone marrow aspirates were obtained from healthy volunteers, and mononuclear cells were
isolated by means of Ficoll density centrifugation and then placed in 10-cm-diameter dishes.
These cells were cultivated in low-glucose Dulbecco’s modified Eagle’s medium (DMEM,
Gibco-BRL, Grand Island, NY, USA) containing 10% fetal bovine serum and 1% penicillin/
streptomycin. The cells were maintained in a humidified incubator at 37°C in 5% CO2, and the
medium containing non-adherent cells was replaced every 3 days. When the cultured cells
reached 70%–80% confluence, they were trypsinized and subcultured. The human MSCs in
passage 5 were used in our experiments [27]. We obtained written informed consents from all
volunteers who agreed to the use of their cells for research purposes.
Flow cytometry
Bone marrow-derived MSCs (1 × 106) were trypsinized, washed with phosphate-buffered
saline (PBS), and incubated with antibodies against CD14, CD29, CD31, CD34, CD44,
CD45, CD73, CD90 (BD Biosciences, San Jose, CA, USA), CD105, and CD106 (Serotec,
Cambridge, UK). Analysis was performed three separate cell preparations using a FACSCali-
bur flow cytometer (BD Biosciences).
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Transplantation of MSCs
Human bone marrow-derived MSCs (2 × 106, passage 5) were suspended in 400 μL of saline.
The suspended MSCs were slowly infused through the tail vein of rats by using a 1-mL syringe.
The control rats received a slow 400-μL infusion of saline.
Brain tissue preparation
All animals were sacrificed through transcardiac perfusion of cold heparinized normal saline
by using a peristaltic pump when they were under deep anesthesia induced by intraperitoneal
injection of Zoletil 50. The collected brains were sectioned into 2-mm-thick coronal blocks by
using a rat brain matrix. The coronal blocks were stained with a 2% 2,3,5-triphenyltetrazolium
chloride (TTC) solution, and infarction sizes were measured in the 1st, 3rd, 5th, and 7th blocks.
The 4th block was cut into the left and right hemispheres, embedded in Tissue-Tek OCT com-
pound (Miles, Inc., Elkhart, IN, USA), quickly frozen using 2-methylbutane and dry ice, and
stored at –80°C until analysis.
Fig 1. Study Design in Experiments 1 and 2. Experiment 1 was conducted to identify the time point of humanmesenchymal stem cell (MSC)
transplantation that led to maximal neurological recovery in rats after middle cerebral artery occlusion (MCAO). In Experiment 2, MSCs were administered at
1 h after MCAO, the time point identified in Experiment 1 as being optimal for enabling maximal neurological recovery. Infarction volume, neurological
recovery, MMP-2 and MMP-9 activity, and vascular density after MCAOwere compared between the MSC 1-hour group and the control group.
doi:10.1371/journal.pone.0144218.g001
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TTC staining and infarction-volume measurement
Fresh blocks were stained with the TTC solution in order to determine infarct volumes. Briefly,
each block from the frontal pole was incubated in a 2% TTC solution at 37°C for 30 min, fixed
with 10% buffered formalin solution, and scanned using a 600-dpi flatbed scanner. The
infarcted areas and whole brain areas in each block were measured by an investigator who was
blinded to the animal group; the areas were measured using Medical Image Processing, Analy-
sis, and Visualization (MIPAV) software (Computer and Information Technology, National
Institutes of Health, Bethesda, MD, USA). The infarction volume was calculated by numeri-
cally integrating the values from individual blocks (1st, 3rd, 5th, and 7th blocks) and dividing by
the whole brain area [25].
Gelatin zymography for measuring MMP activities
MMP-2 and MMP-9 activities were measured using gelatin zymography. The sections were
placed in 120 μL of homogenizing buffer (1% Triton X-100, 50 mmol/L Tris-HCl [pH 7.5], 75
mmol/L NaCl, 1 mmol/L phenylmethyl sulfonyl fluoride (PMSF, Sigma-Aldrich, St. Louis,
MO, USA) and were centrifuged at 9000 rpm for 20 min at 4°C. The supernatant was obtained
from the centrifuged mixture and stored at −80°C. The protein concentration of stored samples
was measured using the Bradford method (Bio-Rad Laboratories, Hercules, CA, USA) and a
bovine gamma globulin standard. Zymography was performed according to previously pub-
lished methods; we mixed 50 μg of purified protein extracts with an equal volume of sample
buffer (pH 6.8, 80 mmol/L Tris-HCl, 4% sodium dodecyl sulfate [SDS], 10% glycerol, 0.01%
bromophenol blue) [18, 22], and then measured the gelatinolytic activities of samples by using
8% SDS-polyacrylamide gels containing 1% gelatin. Sample gels were rinsed in 150 mL of 2.5%
Triton X-100 (15 min × 3) and incubated at 37°C in 250 mL of 50 mmol/L Tris-HCl buffer
(pH 7.5, 10 mmol/L CaCl2, 0.02% NaN3) for 66 h. After incubation, the gels were stained with
a 0.1% amido-black solution containing acetic acid, methanol, and distilled water (volume
ratio 1:3:6) for 1 h, and then destained by washing 4 times for 20 min with the same solution
without amido black. The gels were scanned using a flatbed scanner and the gelatinolytic bands
were quantified using Scion Image software (Scion Corporation, Frederick, MD, USA) and a
gel-plotting macro. Measured values were standardized relative to the sample values of recom-
binant MMP-2 and MMP-9 in each gel.
Immunostaining
Immunohistochemistry was performed for collagen type 4 (1:800; Developmental Studies
Hybridoma Bank, Iowa City, IA, USA). Frozen sections were fixed with methanol for 10 min
and immersed in 100 mmol/L of glycine in PBS for 10 min. To reduce nonspecific staining, the
sections were washed with a PBS solution and incubated with Blotto (5% hydrated nonfat dry
milk containing 1% BSA) for 20 min. After blocking, the sections were incubated with primary
antibodies overnight at 4°C under humidified conditions. After washing with PBS, a biotiny-
lated anti-mouse secondary antibody (Vector Laboratories, Burlingame, CA, USA) was applied
for 30 min at 37°C. Avidin-biotin complexes were generated using streptavidin-horseradish
peroxidase (Vector Laboratories), the peroxidase signal was developed using a 3,30-diamino-
benzidine solution (Vector Laboratories), and the immunostained cells were analyzed using
bright-field microscopy.
To perform immunofluorescence double-labeling, brain tissues were fixed and permeabi-
lized and then stained with primary antibodies against MMP-2 (1:200; Millipore, Milford, MA,
USA), NeuN (1:100; Chemicon, Temecula, CA, USA) for neurons, OX-42 (Serotec; Raleigh,
NC, USA) for microglia, glial fibrillary acidic protein (GFAP, 1:200; Santa Cruz Biotechnology,
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Santa Cruz, CA, USA) for astrocytes, or collagen type 4 (1:800, Developmental Studies Hybrid-
oma Bank) for microvessels. All tissues were then incubated with Cy3-labeled anti-rabbit IgG
and either FITC-labeled anti-goat or anti-mouse IgG (all from Jackson Immunoresearch Labo-
ratories, West Grove, PA, USA). Images were acquired using an Axio Imager.D2 (Zeiss, Ober-
kochen, Germany) equipped with a high-resolution camera (AxioCam HRC, Zeiss).
Vascular density
Wemeasured and compared vascular density at 10 days after MCAO between the MSC 1-hour
group and the control group based on immunohistochemical staining for collagen type 4.
Using the computer-assisted stereological toolbox system (CAST; Olympus Danmark A/S,
Albertslund, Denmark), the number and diameter of the vessels were semi-automatically mea-
sured at 120–260 randomly sampled points per coronal section of the whole brain, which con-
stituted a 10% fraction of the section. Vascular density is expressed as the number of vessels
per unit area (mm2) [28].
To reveal the effect of MMP-2 in angiogenesis, we performed a randomized placebo-con-
trolled, blind experiment. Permuted-block randomization with a block size of 4 was generated
to compare vascular density between animals that were treated with MSCs and a selective
MMP-2 inhibitor (sc-204092, Santa Cruz Biotechnology) and those with MSCs and placebo.
Under inhalation anesthesia with 1.5%–2% isoflurane, animals’ head were placed and fixed on
a stereotaxic frame, and bregma was exposed with a midline incision. Bone was drilled and
removed at 1.5 mm lateral and 0.3 mm posterior to the bregma. A Hamilton needle (32 gauge)
was inserted through the burr hole 4.5 mm deep below the dura to reach to the lateral ventricle
[29]. The selective MMP-2 inhibitor or placebo was administered at 1 h after MCAO. The
selective MMP-2 inhibitor 250 μg/kg or vehicle was intracerebroventricularly infused for 10
min [30]. During the intracerebroventricular infusion, 2 × 106 of MSCs were injected through
the tail vein according to the previous studies [29–31]. Vascular densities were measured at 10
days after MCAO. Gelatin zymography was performed to measure the changes of MMP-2
activity in rat brain obtained at 10 days. Investigators who were blinded to the treatment group
assessed vascular density and gelatin zymography.
Statistical analysis
SPSS for Windows (Version 18.0, SPSS Inc., Chicago, IL, USA) was used for statistical analysis.
For continuous variables, the mean and standard deviation (SD) were calculated and indepen-
dent-sample t tests were used for comparisons. Differences in the results of the neurologic exams
among groups were determined using the repeated measurement analysis of variance (ANOVA)
test followed by Tukey’s post-hoc analysis. P< 0.05 was considered statistically significant.
Results
MSC identity confirmation using flow cytometry
Flow-cytometric analysis of donor MSCs showed that the MSC-specific antigens CD105 and
CD90 [32] were expressed in 99.48% and 99.94% of all cells, respectively. By contrast, the hemato-
poietic progenitor cell antigen CD34 was expressed in only 2.64% of the total cells (S1 Fig).
Physiologic parameters
The physiologic parameters mean arterial blood pressure, pH, PaCO2, PaO2, and hemoglo-
bin were not different between the MSC-treated and control groups before and after MCAO
(S1 Table).
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Experiment 1
Mortality and neurologic outcome. Of the 29 rats used, 2 (7.4%) died because of large
hemispheric infarctions after MCAO (one of the MSC 1-hour group and one of the MSC 1-day
group). Therefore, we performed neurologic assessments on the 27 surviving animals (6, MSC
1-hour group; 6, MSC 1-day group; 7, MSC 3-day group; 8, control group). Before MCAO, the
mean duration of holding on the rotarod cylinder did not differ among the groups (264 ± 44 s
in the MSC 1-hour group, 247 ± 38 s in the MSC 1-day group, 230 ± 25 s in the MSC 3-day
group, and 247 ± 22 s in the control group, P = 0.453). By contrast, the mean durations of hold-
ing on the rotarod cylinder at 1, 4, and 7 days after MCAO were distinct among the groups
(df = 3, F = 3.431, P = 0.034). A post-hoc analysis revealed that the MSC 1-hour group showed
greater recovery in the rotarod test than did the control group (P = 0.023). The Longa score
also differed among the groups (df = 3, F = 1.597, P = 0.03), and this score of the MSC 1-hour
group was lower than that of the MSC 1-day group in the post-hoc analysis (P = 0.018) (Fig 2).
MMP activities. MMP activities in the ischemic hemisphere were measured using gelatin
zymography. The MMP-2 activity of the MSC 1-hour group was higher than that of the control
group (3130 ± 1807 vs. 1087 ± 579, P = 0.028). The MMP-2 activities of the MSC 1-day and
3-day groups were not different from those of the control group. In contrast to MMP-2 activity,
MMP-9 activity did not differ between the MSC-treated groups and the control group (Fig 3).
Fig 2. Behavioral Tests in Experiment 1.MSCs were injected intravenously at 1 h (MSC 1-hour group, n = 7), 1 day (MSC 1-day group, n = 7), or 3 days
(MSC 3-day group, n = 7) after MCAO. The control group received normal saline after MCAO (n = 8). Behavioral tests were performed using the rotarod test
(A) and by measuring the Longa scores (B) before MCAO and at 1, 4, and 7 days after MCAO. At 7 days after MCAO, the results of the rotarod test showed
significant functional recovery in the rats treated with MSCs at 1 h. The Longa scores were also more favorable in the MSC 1-hour group than in the control
group (*P < 0.05).
doi:10.1371/journal.pone.0144218.g002
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Experiment 2
Mortality and neurologic outcomes. Of the 68 rats used, 9 (13.2%) died because of large
hemispheric infarction within 1 day after MCAO (2 of the MSC 1-hour group and 7 of the con-
trol group, P = 0.15). Baseline results of the rotarod test were not different between the groups
(117 ± 32 s in the MSC 1-hour group, 122 ± 50 s in the control group, P = 0.552). However, the
performance of the MSC 1-hour group on the rotarod cylinder was superior to that of the con-
trol group at 10 days after MCAO (63 ± 28 vs. 27 ± 21 s, P = 0.013) and also at 14 days after
MCAO (70 ± 25 vs. 25 ± 20 s, P = 0.027) (Fig 4A). The modified NSS did not differ between
Fig 3. MMP-2 and -9 Activities Revealed Using Zymography.MMP activities in the ischemic hemisphere were measured using gelatin zymography. The
MSC 1-hour group showed higher MMP-2 activity than did the control group (P = 0.028). However, MMP-2 activity was not distinct between the MSC 1-day or
3-day group and the control group (A). MMP-9 activity was not different between the MSC-treated groups and the control group (B).
doi:10.1371/journal.pone.0144218.g003
Fig 4. Neurological Recovery and Infarction Volume. The surviving animals (MSC 1-hour group, n = 32; control group, n = 27) were subjected to
behavioral tests by using the rotarod test and by measuring the modified Neurologic Severity Score (NSS) at baseline and at 1, 4, 7, 10, and 14 days after
MCAO. In the rotarod test, the MSC 1-hour group exhibited statistically significant functional recovery at 10 and 14 days (A). The modified NSS at 14 days
also revealed greater recovery in the MCS 1-hour group than in the control group. Because the modified NSS scores at 14 days of all 4 rats in control group
were 7, the error bar could not be drawn (B). The infarction volume was smaller in the MSC 1-hour group than in the control group at 10 and 14 days after
MCAO (C).
doi:10.1371/journal.pone.0144218.g004
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the MSC 1-hour group and the control group until 10 days after MCAO; however, at 14 days,
the recovery exhibited by the MSC 1-hour group was superior to that of the control group (4.4
points in the MSC 1-hour group vs. 7 points in the control group, P = 0.01) (Fig 4B).
Infarction volumes. Until 7 days after MCAO, infarction volumes did not differ between
groups. However, at 10 and 14 days after MCAO, the infraction volume was smaller in the
MSC 1-hour group than in the control group (10 days: 13.9% ± 1.5% vs. 18.9% ± 2.1%,
P = 0.028; 14 days: 11.8% ± 2.58% vs. 16.8% ± 1.1%, P = 0.01) (Fig 4C).
MMP activities. MMP-2 activities increased over time in both the MSC 1-hour group and
the control group until 7 days after MCAO. Comparison of the MSC 1-hour and control
groups showed that MMP-2 activity in the MSC 1-hour group was significantly higher than
that in the control group at 1 day after MCAO (828 ± 119 vs. 360 ± 203, P = 0.002). By contrast,
MMP-9 activities of the MSC 1-hour and control groups were not different. Increased MMP
activities measured after MCAO were decreased starting from 10 days (MMP-2) and 7 days
(MMP-9) (Fig 5).
Vascular density after MSCs treatment. Vascular density, which was determined based
on collagen type 4 staining, was increased to a greater extent in the MSC 1-hour group than in
the control group at 10 days after MCAO. Quantification revealed that the number of large-
sized vessels (>10 μm) was significantly higher in the MSC 1-hour group than in the control
group (P = 0.036) (Fig 6A).
Vascular density after MMP-2 inhibition. During 10 days of follow-up after the intracer-
ebrolventricular administration of a selective MMP-2 inhibitor or placebo, 6 of the10 MMP-2
inhibitor-treated rats and 7 of the 10 placebo-treated rats were died. Of survived rats, vascular
density was not significantly different between groups [p = 0.261 for small-sized capillaries (1–
5 μm), p = 0.793 for medium-sized capillaries (5–10 μm), and p = 0.667 for large-sized vessels
(>10 μm)] (Fig 6B).
Fig 5. MMP-2 and -9 activities in the Ischemic Hemisphere. The MMP-2 activity in the MSC 1-hour group was significantly higher only at day 1 after IV
infusion. Although remains higher subsequently, it did not remain statistically significant (A). By contrast, MMP-9 activity in the MSC 1-hour group was not
significantly different from that in the control group. The increased MMP activities measured after MCAO decreased starting from 10 days (MMP-2) and 7
days (MMP-9) (B).
doi:10.1371/journal.pone.0144218.g005
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Immunofluorescence staining. Immunofluorescence staining revealed that MMP-2 was
neither colocalized with NeuN nor OX-42, but was colocalized with GFAP and was detected at
the outer rim of the staining for collagen type 4, which suggested that MMP-2 was expressed in
astrocytes (Fig 7).
Discussion
This study showed that maximal neurological improvement occurred when MSCs were trans-
planted very early (1 h) after MCAO, and that the improvement was apparent at about 10 days
after treatment.
Therapeutic time window of IV MSC transplantation is unknown. Earlier treatment with
MSCs mediates neuroprotection in acute period and may allow functional recovery. Only a few
studies have investigated the effect of MSC transplantation during the hyperacute period (<3
h). Most previous studies tested the efficacy of IV MSCs therapy form 24 h to 1 month [23, 26,
33, 34]. Although, transplantation of MSCs at 24 h or delayed time injection showed neurologi-
cal recovery, it did not decrease the infarction volume in a statistically significant manner [6,
35–38], which suggests that MSC transplantation at this time point is likely insufficient for
reverting tissue damage.
In contrast to previous studies, the transplantation of MSCs at 1 and 3 days did not improve
functional outcome in this study. This might be partly ascribed to the difference of a stroke
model. We used a permanent MCAOmodel while others did a transient MCAmodel. The per-
manent MCAmodel induces more severe ischemic injury and less delivery of MSCs to infarct
core than the transient MCAOmodel. We also used later passages of MSCs (5 passage MSCs).
These factors might have resulted in less effect in rats treated at 1 or 3 days in our experiment.
Fig 6. Vascular Density.Using the computer-assisted stereological toolbox system, the number and the diameter of vessels were measured based on
immunohistochemical staining for collagen type 4 at 10 days after MCAO. The number of the larger capillaries (>10 μm) was significantly higher in the MSC
1-hour group than the control (P = 0.036) (A). After the intracerebrolventricular administration of a selective MMP-2 inhibitor or placebo, vascular density was
not significantly different in all ranges of vessel diameter (B).
doi:10.1371/journal.pone.0144218.g006
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The different recipient species, cell sources of donors, and doses of MSCs might also influence
the result (S2 Table).
IA delivery of MSCs at 1 h after 90 min of transient MCAO using a lower dose of MSCs
(1X105) was not superior to controls, while the IA delivery at 24 h after transient MCAO
showed superior functional outcomes and smaller infarctions as compared to controls [8]. The
number of cells (1X105) in that study was chosen based on arterial blood flow measurement
using a laser Doppler study, which did not show decrease in the cerebral blood flow. Although
the cells that were delivered by IA route might not occlude the artery or arteriole, they could
have impeded microcirculation at the capillary level. The ischemic penumbra area is much
more sensitive to decrease in blood flow during hyperacute period than later stage of cerebral
ischemia. Consequently, the beneficial effects of MSCs might be neutralized by the negative
effect of impeded microcirculation during hyperacute period (1 h after transient MCAO), but
not at 24 h after transient MCAO. This issue may be better resolved by the direct comparison
of IV and IA delivery at the same time.
Our observations showing an increase of vascular density at 10 days after MCAO suggest
that MSC treatment in the hyperacute stage might trigger angiogenesis, which, in turn, would
result in recovery from ischemic injury and functional improvement. Previous study showed
that IV injection of human MSCs (1 X 106) at 24 h after MCAO can promote endogenous
VEGF secretion, VEGF receptor 2 expression and increased angiogenesis [10]. Angiogenesis is
correlated with functional improvement in both animal models of stroke and human stroke
[39]. Stroke patients exhibiting a high cerebral blood vascular density showed better prognosis
and longer survival than did patients exhibiting lower vascular density [40]. Cerebral ischemia
itself induces neovascularization within the ischemic boundary zone [41], and angiogenesis is
essential for repairing injured cerebral tissues.
Fig 7. Immunofluorescence staining for MMP-2, NeuN, GFAP, OX-42, and Collagen type 4.
Immunofluorescence staining showed that MMP-2 was not colocalized with neurons (NeuN) or microglia
(OX-42), but it was colocalized with astrocytes (GFAP) and and was detected at the outer rim of the capillary
basement membrane (collagen type 4), Scale bar = 50 μm.
doi:10.1371/journal.pone.0144218.g007
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Proliferation of endothelial cells begins as early as 12–24 h after a stroke, and the increase in
the number of vessels is apparent 3 days after ischemic injury [42]. Further formation of new
stable vasculature takes a few weeks (7–28 days) [43]. Newly formed vessels improve tissue per-
fusion and enhance subsequent angiogenesis and promote functional recovery after stroke
[10]. Before endothelial proliferation begins, most of the well-known angiogenic factors includ-
ing VEFG and angiopoietin-2 show increased expression as early as a few hours after ischemia
[44]. Besides influencing recognized angiogenic factors, MSC transplantation triggers the
secretion of unidentified factors and might thus enhance the angiogenic process [45].
One of the critical events required for successful angiogenesis is extracellular proteolysis,
which involves the degradation of the vascular basement membrane and the activation of cyto-
kines [46]. Therefore, we measured the activity of MMP-2 and MMP-9 after MSC transplanta-
tion. MMPs are key proteolytic enzymes that mediate the degradation of the vascular ECM.
The expression levels of MMP-9 and MMP-2 have been reported to start increasing from 12 h
to 2 days and from 2 to 5 days after cerebral ischemia, respectively [15]. These temporal profiles
of expression after cerebral ischemia suggest a role of MMP-9 in secondary tissue damage and
that of MMP-2 in tissue repair [14].
MMP-2 critically affects vascular development and angiogenesis. Angiogenesis is reduced in
MMP-2 knockout mice and following treatment with natural or synthetic inhibitors of MMP-2
[21]. A clinical study showed that basal MMP-2 levels were higher in patients exhibiting stable
or recovering symptoms than in other patients [47]. In this context, early MMP-2 elevation
after ischemia might be beneficial because MMP-2 is a crucial protease involved in blood vessel
remodeling through angiogenesis [10, 44, 48]. However, vascular density was not changed by
intracerebroventricular infusion of a selective MMP-2 inhibitor in this study. This finding sug-
gests that pro-angiogenic effects of MSCs transplantation may not be solely mediated by
MMP-2. MSC behave as a small biochemical factory producing trophic factors (e.g., VEGF/
Flk1 and Ang1/Tie2) or induce endogenous VEGF and VEGFR2 expression [44, 49]. These
factors also might be related with promoting angiogenesis. Further experiments may be
required to address the mechanism of increased vascular density after MSCs transplantation.
This study has limitations. First, producing the beneficial effects of early MSC transplanta-
tion in patients with acute ischemic stroke might not be practical, because expanding human
MSCs in order to perform autologous transplantation takes one month. Thus, further studies
are required to bridge the gap between animal experiments and clinical trials. Second, in this
study, we used a rat model and permanent MCAO, and results could differ between species or
between permanent and transient ischemic stroke models. Third, we used later passages of
MSCs while the use of earlier passage of cell may show better efficacy. Culturing up to later pas-
sages can increase the number of cells. It had been reported that MSCs with passage 5 or 6 are
the earliest passages to achieve a sufficient IV dose of MSCs in human [50]. We wanted to bal-
ance between the efficacy of MSCs and limited amounts of human MSCs. Finally, MSC is
reported as relatively immune privileged in allogeneic transplantation and allogeneic trans-
plantation of MSCs has been reported to be safe and effective. We used xenogeneic model
using human MSCs. Recent meta-analysis revealed that the effect was better when the source
of MSCs was human than it was rat or mouse even in xenogeneic approach [51]. Because allo-
geneic “off the shelf”MSCs can be used in clinical settings allowing for very early transplanta-
tion, IV infusion of allogeneic MSCs may be possible in clinical trials.
In conclusion, our study showed that very early transplantation of humanMSCs in a perma-
nent model of rodent MCAO improved neurologic outcomes and decreased infarction volume
after ischemia. The increases in MMP-2 activity and vascular density after MSC transplanta-
tion suggest that MSC treatment may help promote angiogenesis, which would result in neuro-
logic improvement during the recovery phase.
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